Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

POSEIDON Delivers For AstraZeneca's Imfinzi, But More Clarity Is Needed

Executive Summary

Imfinzi and tremelimumab plus chemotherapy improved PFS in first-line NSCLC, but overall survival is continuing to be assessed, and AstraZeneca did not clarify how the triple combination compared to Imfinzi alone with chemotherapy.

You may also be interested in...



Bristol Projects Opdivo Sales Will Grow Again In 2021

With new Opdivo/Yervoy combination data in first-line lung cancer, the company expects the PD-1 inhibitor’s growth to go from flat to rising in 2021. Bristol’s and Celgene’s third quarter earnings exceeded expectations and their merger is on track to close this year.

Merck Confident In Keytruda’s Dominance In Lung Cancer, Despite Competitors’ Data

With Keytruda sales of more than $3bn during Q3 and roughly 80% market share in lung cancer, Merck indicates little worry about recent data readouts for BMS and AstraZeneca in NSCLC.

An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer

CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC126099

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel